Survival after nephrectomy for various kidney cancer subtypes

Data presented at the American Urological Association (AUA) 2021 meeting last month shows that 5-year survival rates following partial or radical nephrectomy for renal cell carcinoma (RCC) vary depending on the histology of the RCC subtype. The results of this study have implications for developing personalised therapies to target high-risk, aggressive tumours. The researchers identified […]

read more

Cellular signatures of kidney tumours

The origins of seven types of kidney cancer, including several rare subtypes, have been identified by researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH), the Princess Máxima Center for Paediatric Oncology and Oncode Institute. The findings confirm that these cancers originated in developmental cells found in the foetus. The results from the […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

The most complete catalogue of clear cell renal cell carcinoma (ccRCC)

Researchers at the University of Texas (UT) Southwestern Medical Center have developed what could be the most complete catalogue of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. This cancer is very diverse in character (heterogenous) and there is high variability in tumours. This heterogeneity makes is difficult to diagnose […]

read more

New subtypes of kidney cancer identified

Using advanced proteogenomic technologies to look at genetic makeup and proteins, researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) in America have identified four subtypes of clear cell renal cell carcinoma (RCC). The researchers found that almost all of the clear cell RCC tumour samples in the study lacked chromosome 3p. […]

read more

ASCO GU 2019: When to obtain genetic testing for renal cell carcinoma

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Shuch provided a summary and guide to genetic testing for syndromic renal cell carcinoma (RCC). There is an established strong inheritance pattern in kidney cancer, and now there are 15+ recognised […]

read more

An overview of the management of rare subtypes of kidney cancer

This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in Bethesda, USA, discusses the management of sarcomatoid renal cell carcinoma (RCC), papillary RCC, and hereditary RCC, such as hereditary leiomyomatosis RCC (HLRCC). Watch the interview with Dr Srinivasan on Practice Update here

read more

Sunitinib vs everolimus for advanced non-clear cell kidney cancer

In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with […]

read more

Largest genomic study of kidney cancer

  Researchers in America have recently completed a study that analysed close to 900 kidney cancers at the molecular level. The team discovered that what have historically been considered three major types of kidney cancer according to their characteristics under the microscope (clear cell, papillary and chromophobe), could be further classified into nine major subtypes through molecular […]

read more
Showing all 9 results
  TOP